Mozart Therapeutics Presents MTX-101 Data for Type 1 Diabetes
05 Nov 2024 //
PR NEWSWIRE
Mozart Therapeutics Doses First Cohort In Phase 1a/b Trial Of MTX-101
17 Jun 2024 //
PR NEWSWIRE
Mozart Therapeutics Raises $25 Million in Expanded Series A Financing
07 Jun 2023 //
PR NEWSWIRE